7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis

      research-article
      a , b , a , a , a
      Drug Delivery
      Taylor & Francis
      circVMP1, cisplatin, miR-524-5p, METTL3, SOX2, exosome

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Circular RNAs (circRNAs) play important regulatory roles in multiple human malignancies, including non-small cell lung cancer (NSCLC). Here, we explored the role of circRNA vacuole membrane protein 1 (circVMP1) in NSCLC progression and cisplatin (DDP) resistance.

          Methods

          The DDP resistance, proliferation, sphere formation ability, migration, invasion, and apoptosis of NSCLC cells were analyzed by Cell Counting Kit-8 (CCK8) assay, 5-ethynyl-2′-deoxyuridine (EdU) assay, sphere formation assay, wound healing assay, Transwell assay, and flow cytometry. Methylated RIP-qPCR (MeRIP-qPCR) was conducted to analyze the m 6A modification level of SRY-box transcription factor 2 (SOX2). Dual-luciferase reporter assay, RNA immunoprecipitation (RIP) assay, and RNA-pull down assay were performed to confirm the intermolecular interaction. Exosomes were identified by transmission electron microscopy (TEM) and characterized by nanoparticle tracking analysis (NTA).

          Results

          CircVMP1 expression was markedly elevated in DDP-resistant NSCLC cell lines compared with their parental cell lines. CircVMP1 absence restrained the proliferation, sphere formation, migration, invasion, and DDP resistance and promoted the apoptosis of DDP-resistant NSCLC cells. CircVMP1 acted as microRNA-524-5p (miR-524-5p) sponge to up-regulate the expression of methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit (METTL3) and SOX2. CircVMP1 silencing restrained the malignant behaviors and DDP resistance of A549/DDP and H1299/DDP cells by targeting miR-524-5p. Exosomal circVMP1 disseminated the malignant properties and DDP resistance to DDP-sensitive cells. Exosomal circVMP1 elevated the DDP resistance of xenograft tumors in vivo. Exosomal circVMP1 was up-regulated in the serum samples of DDP-resistant NSCLC patients compared with DDP-sensitive patients.

          Conclusion

          Exosome-mediated transmission of circVMP1 promoted NSCLC progression and DDP resistance by targeting miR-524-5p-METTL3/SOX2 axis.

          Highlights
          • CircVMP1 level is up-regulated in DDP-resistant NSCLC cell lines compared with DDP-sensitive cell lines.

          • CircVMP1 absence restrains the malignant behaviors and DDP resistance of A549/DDP and H1299/DDP cells.

          • CircVMP1-miR-524-5p/METTL3/SOX2 axis is identified for the first time.

          • CircVMP1 plays an oncogenic role by targeting miR-524-5p-METTL3/SOX2 axis in A549/DDP and H1299/DDP cells.

          • Exosomal circVMP1 transmits the malignant properties and DDP resistance to DDP-sensitive cells.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          The biology and management of non-small cell lung cancer.

          Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Exosomes: composition, biogenesis and function

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

              Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.
                Bookmark

                Author and article information

                Journal
                Drug Deliv
                Drug Deliv
                Drug Delivery
                Taylor & Francis
                1071-7544
                1521-0464
                25 April 2022
                2022
                25 April 2022
                : 29
                : 1
                : 1257-1271
                Affiliations
                [a ]Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , Suzhou, China
                [b ]Department of Thoracic Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University , Suzhou, China
                Author notes

                Supplemental data for this article can be accessed here.

                CONTACT Bin Ni nibin1203@ 123456163.com Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Gusu District, Suzhou, Jiangsu, 215006, China
                Article
                2057617
                10.1080/10717544.2022.2057617
                9045767
                35467477
                b1a8da0e-83e5-462c-9b54-6a543ac61a26
                © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Figures: 10, Tables: 1, Pages: 15, Words: 8048
                Categories
                Research Article
                Research Article

                Pharmacology & Pharmaceutical medicine
                circvmp1,cisplatin,mir-524-5p,mettl3,sox2,exosome
                Pharmacology & Pharmaceutical medicine
                circvmp1, cisplatin, mir-524-5p, mettl3, sox2, exosome

                Comments

                Comment on this article